Actively Recruiting
Improving Breast Cancer Staging With 18F-FDG PET/CT Imaging (The IMBRECAS PET Study)
Led by Vestre Viken Hospital Trust · Updated on 2024-05-09
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 18F-FDG PET/CT imaging to detect breast cancer metastases that conventional imaging methods like CT and bone scintigraphy might miss. This study focuses on women diagnosed with stage II/III or locoregional recurrent breast cancer, aiming to see if this imaging can improve disease staging and influence treatment decisions. It also explores how imaging and molecular characteristics may relate to patient outcomes such as overall survival and progression-free survival. Participants will undergo an 18F-FDG PET/CT scan in addition to the usual CT and bone scintigraphy imaging as part of their cancer assessment. The study includes patients with newly diagnosed high-risk breast cancer or suspected/proven locoregional recurrent breast cancer. The main goal is to determine if the PET/CT scan leads to changes in staging or treatment plans compared to conventional imaging alone. During the study, researchers will collect imaging data, including PET parameters and CT/MRI measurements, as well as blood and tumor samples for molecular analysis. They will monitor changes in cancer staging and management over five years, along with overall survival. Participants' health status will be assessed using the ECOG performance scale, and safety and outcomes will be followed throughout the study period, which runs until 2032.
CONDITIONS
Brief Title
18F-FDG PET/CT Imaging for Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with high risk primary or recurrent breast cancer
- Non pregnant women over 18 years old
- Not receiving active treatment of other cancer types
- Eastern Cooperative Oncology Group (ECOG) status 0-2
You will not qualify if you...
- Pregnant women
- Males
- Age under 18
- Patients receiving active treatment for other cancers
- Poor general condition (ECOG 3 or higher)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants undergo an 18F-FDG PET/CT scan in addition to conventional imaging to improve breast cancer staging.
1 visit (in-person)
Duration - 5 years
Participants are monitored for changes in cancer staging and overall survival over time.
Trial Site Locations
Total: 1 location
1
Drammen Hospital - Vestre Viken HF
Drammen, Norway, N-3004
Actively Recruiting
Research Team
H
Harald Grut, MD, PHD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here